From Image to InSight with RetInSight: Identify disease activity & therapeutic response in GA and nAMD
RetInSight is your partner in advancing ophthalmology with AI.
We bring transformative AI-based medical software to eye care professionals, revolutionizing the management of all types of age-related macular degeneration (AMD), e.g. intermediate AMD, geographic atrophy (GA), and neovascular (n)AMD.
Leading in AI innovations:
Data-driven insights for time-saving precision care
Pioneering MDR CE-certified AI for eye care professionals
RetInSight was the first company to introduce MDR CE-certified AI solutions for use in clinical routine by eye care professionals. We offer AI-based OCT image analyses with a clear mission: Empowering eye care professionals to offer optimal management of retinal disease to every patient.
Seamless integration into current OCT routine
The solutions are intended to be compatible with routine OCT systems and are integrated in the following PAC systems (PACS = Picture Archiving and Communication System):
- Heidelberg Engineering Spectralis OCT with HEYEX 2.6 / AppWay
- Topcon Triton OCT with Harmony
Compliance-driven
Regulatory requirements, including FDA regulations in the U.S. and MDR in Europe, mandate that AI algorithms be validated and certified individually for each device, ensuring full regulatory compliance for every specific OCT system.
Regulatory excellence
Our medical software fulfills highest quality and regulatory compliance standards: GDPR, HIPAA, MDR 2017/745, ISO 13485, ISO 27001.
Our AI-based clinical decision support systems offer:
- Precise and objective assessment of disease activity and therapeutic benefit by routine OCT
- Customized PDF report for physicians and patients
- Fully automated visualization and quantification to support an efficient workflow
FAQs
What does “AI in clinical routine” mean in the context of OCT imaging?
AI in clinical routine refers to the use of CE-certified software as medical device (SaMD) compliant with EU MDR, UK MDR, TGA, and Medsafe requirements, that automatically analyzes OCT scans and provides quantitative information for fluid- and GA-related biomarkers.
These tools are designed to support eye care professionals in evaluating retinal structure during everyday clinical eye care workflows.
For which patient groups are AI based OCT analysis tools intended?
RetInSight’s clinical routine tools are intended for:
- Fluid Monitor for patients diagnosed with nAMD
- GA Monitor for patients diagnosed with geographic atrophy
Additional tools will follow as new disease‑specific algorithms are validated.
They provide quantitative, OCT‑based information that clinicians may use as additional input during routine evaluation and follow‑up.
How does AI integrate into existing OCT workflows?
The AI analysis is integrated directly into the Spectralis OCT workflow using the existing PACS systems (Heyex 2.6/AppWay).
Once the OCT scan is acquired, the AI analysis runs in the background, and results become available in the PACS without requiring additional steps or extra imaging sessions.
What benefits does OCT based AI analysis offer compared to manual evaluation?
AI provides a reproducible quantification, independent of operator experience.
It supports longitudinal comparison, consistent documentation, and the visualization of structural changes in retinal diseases.
What are the data privacy and security measures when using AI in clinical routine?
All OCT data processed by RetInSight’s tools is pseudonymized, encrypted in transit and at rest, and handled in compliance with GDPR, ISO 27001, EU AI Act and MDR requirements.
No personally identifiable information (PII) is stored.
Experience precision and insight firsthand: Your journey from image to insight starts with RetInSight.
Request a demo of our transformative Fluid Monitor and GA Monitor to experience the future of efficient ophthalmology care today.